Trinity Biotech (TRIB) Convertible Debt (2021 - 2024)

Trinity Biotech has disclosed Convertible Debt across 4 years of filings, most recently posting $15.4 million for Q4 2024.

• Convertible Debt for Q4 2024 came in at $15.4 million, up 5.91% year-over-year; the trailing twelve-month figure through Dec 2024 was $15.4 million (up 5.91% YoY), and the FY2024 annual result was $15.4 million, up 5.91% from the prior year.
• Convertible Debt came in at $15.4 million for Q4 2024 at Trinity Biotech, up from $15.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $83.3 million in Q4 2021 to a low of $13.4 million in Q2 2022.
• The 4-year median for Convertible Debt is $14.4 million (2023), against an average of $20.1 million.
• Across the five-year window, Convertible Debt sank 83.5% in 2022 and advanced 5.91% in 2024, its largest moves.
• Trinity Biotech's Convertible Debt stood at $83.3 million in 2021, then tumbled by 83.5% to $13.7 million in 2022, then advanced by 5.79% to $14.5 million in 2023, then increased by 5.91% to $15.4 million in 2024.
• The last three Convertible Debt figures came in at $15.4 million (Q4 2024), $15.2 million (Q3 2024), and $15.0 million (Q2 2024), per Business Quant data.